ArticleCell communication and signaling : CCS2026
The P2X4 purinergic receptor controls the autophagy-related release of small extracellular vesicles from mammary cancer cells under hypoxia.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundSmall extracellular vesicles (sEVs) are critical mediators of cell communications and are influenced by cellular stress. This study investigates the role of P2X4 and P2X7 purinoreceptors in the biogenesis and release of sEVs from triple-negative mammary cancer cells under hypoxia.
methodsIn this study, we used CRISPR/Cas9 knockdown models from the triple-negative mammary cancer cell line 4T1 and selective pharmacology, to knock-down or inhibit either P2X4 or P2X7 receptors. We analysed intracellular endo-lysosomal compartments with transmission electron microscopy and epifluorecence imaging. The release and characterization of sEVs was analysed by nanoparticle tracking analysis, proteomics and western blotting. The incorporation of sEVs into recipient cells was followed by epifluorescent imaging and flow cytometry and consequences on cancer cell invasiveness was studied using transwell assays.
resultsWe found that P2X4 but not P2X7 regulates sEV release. P2X4 silencing increased the number of multivesicular bodies (MVBs), enhanced sEV production and selectively promoted CD9-positive sEV subpopulations under hypoxia. Proteomic analysis revealed altered sEV protein content in P2X4-deficient cells, including enrichment in epithelial markers and autophagic proteins (LC3-II, p62), and depletion of the endosomal sorting complexes required for transport (ESCRT) components required for endo-lysosomal fusion. This profile indicates a shift toward autophagy-dependent, unconventional sEV secretion via amphisomes. Additionally, sEVs from P2X4-deficient cells integrated more efficiently into recipient cancer cells but decreased their invasive capacity, suggesting functional consequences of altered sEV cargo. In contrast, intervention of P2X7 had no impact on sEV release.
conclusionsOverall, our findings identify the P2X4 receptor as a key regulator of hypoxia-induced sEV secretion and composition through modulation of endo-lysosomal trafficking and autophagy, with potential implication for tumour progression and intercellular signalling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.